Engineered CD4 TCR T Cells with Conserved High-Affinity TCRs Targeting NY-ESO-1 for Advanced Cellular Therapies in Cancer

Researchers screened HLA-DRB3*02:02 patients with melanoma for tumor-specific CD4 T cells and identified robust New York esophageal squamous cell carcinoma 1/HLA-DRB3*02:02 CD4 T cell activity in both peripheral blood and tumor tissue.